Beta-Blocker Therapy in Hypertension: A Need to Pause and Reflect

Journal of the American College of Cardiology

Volumn 51, Issue 4, 2008, Pages 516-517

  Giles, Thomas D ^a   Bakris, George L ^a   Weber, Michael A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; METOPROLOL; TRANDOLAPRIL PLUS VERAPAMIL;

BETA ADRENERGIC RECEPTOR BLOCKING; DRUG EFFECT; DRUG EFFICACY; DRUG MONITORING; DRUG USE; HUMAN; HYPERTENSION; LETTER; PATIENT ASSESSMENT; PRIORITY JOURNAL; PROFESSIONAL KNOWLEDGE; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADRENERGIC BETA-ANTAGONISTS; DRUG EVALUATION; HUMANS; HYPERTENSION; TREATMENT OUTCOME;

EID: 38349092032     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2007.09.050     Document Type: Letter

References (10)

1. Bangalore S., Messerli F., Kostis J., and Pepine C. Cardiovascular protection using beta-blockers. A critical review of the evidence. J Am Coll Cardiol 50 (2007) 563-572
2. Lindholm L.H., Carlberg B., and Samuelsson O. Should beta-blockers remain first choice in the treatment of primary hypertension?. A meta-analysis. Lancet 366 (2005) 1545-1553
3. Dahlöf B., Lindholm L.H., Hansson L., Schersten B., Ekbom T., and Wester P.O. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 338 (1991) 1281-1285
4. Hansson L., Lindholm L.H., Ekbom T., et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 354 (1999) 1751-1756
5. Pepine C.J., Handberg E.M., Cooper-DeHoff R.M., et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil Trandolapril Study (INVEST): a randomized controlled trial. JAMA 290 (2003) 2805-2816
6. UKPDS Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ 317 (1998) 713-720
7. Bakris G.L., Fonseca V., Katholi R.E., et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 292 (2004) 2227-2236
8. Brixius K., Middeke M., Lichtenthal A., Jahn E., and Schwinger R.H. Nitric oxide, erectile dysfunction and beta-blocker treatment (MR NOED study): benefit of nebivolol versus metoprolol in hypertensive men. Clin Exp Pharmacol Physiol 34 (2007) 327-331
9. Celik T., Iyisoy A., Kursaklioglu H., et al. Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients. J Hypertens 24 (2006) 591-596
10. Mancia G., De Backer G., Dominiczak A., et al. 2007 guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 28 (2007) 1462-1536